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OBJECTIVES:  Mammary  hamartoma  is  a  rare  benign  lesion  accounting  for  approximately  4.8% of  all  benign
breast  masses.  It is often  underdiagnosed  and  therefore  is  underreported  mostly  due to  lack of awareness
of the characteristic  clinical  and  histological  features.  Raising  awareness  of this  poorly  recognized  benign
entity is of utmost  signiﬁcance  as  it  clinically  mimics  other  breast  tumors  including  both  benign  and
malignant  ones.  This study  is to  report  and  present  our  experience  of  breast  hamartomas  from  Johns
Hopkins  Aramco  Healthcare  in  the  Eastern  province  of Saudi  Arabia  from  which  there  have  not  been
previous  studies  in literature.
METHOD:  A retrospective  review  of our pathology  ﬁles  was  done  from  1994  to 2014  for  cases  diagnosed
as  breast  hamartoma  during  this  20 year  period.
RESULTS:  A  total  of 14 cases  with  diagnosis  of breast  hamartoma  were  identiﬁed  in our institute.  Histo-
logically  the  lesion  is mostly  sharply  demarcated  showing  a mixture  of varying  proportions  of  ﬁbrous,
adipose,  and  glandular  tissue.  13  cases  were  seen  in  females  (93%)  and  only  one  rare  occurrence  in a male
patient  (7%).  The  age  ranges  quite  vastly  from  18  to 51  years  (mean  33  years).  Two-third  of these  lesions
were  seen  involving  the right  breast  (9 cases/64.3%)  and  only  one-third  in  the left  side (5 cases/35.7%).
13  out  of  14  patients  had  a well  circumscribed  lesion  (92.9%)  while  only  1 case  showed  irregular  borders
(7.1%).  The  size  varied  from  1.4  to 9.5 cm.  Three  cases  (21.4%)  showed  evidence  of  myoid  differentiation,  a
histopathologic  variance  which  is  important  to  identify  however  has  no  clinical  signiﬁcance.  3 cases  had
associated  epithelial  ductal  hyperplasia  of  the  usual  type  varying  from  mild  (2 cases)  to  moderate  (1  case);
with  two  of  these  cases  exhibiting  additional  features  of ﬁbrocystic  mastopathy  including  adenosis,  apoc-
rine metaplasia,  and  cyst  formation.  None  of our cases  showed  any  malignancy  or pseudoangiomatous
stroma  hyperplasia  (PASH).
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. Introduction
Breast hamartoma is a well-demarcated mostly encapsulated
odule representing as a mass composed of haphazardly arranged
reast tissue components. The lesion was initially described in
968 by Hogeman and Osbterg, and the term “hamartoma” was
ntroduced back in the year 1971 by Arrigoni et al. There are sev-
ral variants described depending on the composition of glandular
nd ﬁbroadipose elements that include adenolipoma, ﬁbroade-
olipoma, and myoid hamartoma, the latter shows prominent
mooth muscle proliferation. The pathogenesis of the development
f a breast hamartoma is still not fully understood. Pathologically,
amartomas lack a distinguishing appearance. And clinically, it is
ften discovered incidentally during screening mammography, and
s considered to be underdiagnosed. However, with the increase
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reativecommons.org/licenses/by-nc-nd/4.0/).shed  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
 BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
in the usage of breast diagnostic procedures such as ultrasound,
mammography, core needle and ﬁne needle aspiration biopsy, the
number of breast hamartomas discovered is on the rise. It is impor-
tant to note that the lesion can be easily missed if not appreciated
by clinical examination or radiologically. Herein, we report 14 cases
of breast hamartomas including 3 myoid hamartomas.
2. Materials and methods
We performed a retrospective review of all breast cases seen in
our institute from 1994 to 2014. A total of 14 cases were identiﬁed
(Table 1).
3. ResultsUpon retrospective review of all breast cases seen in our insti-
tute during the period of 1994–2014, a total of 14 cases of breast
hamartomas were identiﬁed (Table 1). They all presented as soli-
tary nodules, the majority being in female patients (93%) with only
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Dig. 1. Mammary glandular tissue admixed with adipose tissue and smooth muscle
bers in ﬁbrotic background.
ne case diagnosed in a male patient (7%). The age ranged from 18
o 51 years (mean, 33). Lesions were found in the right breast in a
igniﬁcantly higher amount in comparison to the left breast with
 ratio of 9:5 (64.3% and 35.7% respectively). 13 of the 14 patients
resented with well circumscribed nodules (92.9%), with only one
ase having a nodular lesion with irregular borders (7.1%). The size
f the lesions ranged from 1.4 to 9.5 cm.  Two of the lesions were
airly well encapsulated with the majority of others showing a rim
f pseudocapsule.
Histologically the lesions showed a haphazard admixture ofenign mammary glandular tissue, fat, and ﬁbrous strands present
n varying proportions. Three cases, in addition, showed bundles
f benign appearing spindled smooth muscle cells (Figs. 1 and 2).
able 1
emographics and clinicopathalogic features of 14 cases of breast hamartoma.
# Age Site (R/L) Lesion Size Lesion Description 
1 28 Left 2 × 1.6 × 1 cm Discrete well circumscribed n
2  51 Left 9.5 × 6.5 × 2.8 cm Lobulated, well circumscribed
section; soft lobulated white t
foci of yellow fatty tissue and
tissue
3  32 Right 3 × 2 × 1.5 cm Well circumscribed whitish ta
occasional clefts
4  39 Right 3.5 × 1 × 1 cm Fibrofatty nodular appearance
5  21 Right 4.3 × 4 × 2.8 cm Well circumscribed ﬁrm tan ﬁ
with smooth cut surface
6  22 Left 1 × 0.8 × 0.5 cm Well circumscribed nodule w
rubbery tan cut surface
7  35 Right 1.5 × 3.4 × 2.1 Circumscribed tan white lobu
with homogenous tan cut sur
8 42 Left 2 × 1 × 0.5 Circumscribed nodular rubbe
homogenous soft white cut su
area of yellow fatty tissue
9  18 Right 2 × 1.4 × 0.7 cm Oval nodule of rubbery white
attached scanty fatty tissue an
soft tan cut surface
10 43 Right 5.3 × 3.8 × 2.7 cm Lobulated fatty nodular tissue
area of ﬁrm tan cut surface
11  39 Right 5.5 × 4.5 × 3.5 cm Nodule of fatty tissue with thi
and homogenous yellow soft 
12  42 Right 6 × 5.5 × 3 cm Well circumscribed ﬁbrofatty
13  35 Left 3 × 2.3 × 2.4 cm Well circumscribed lobulated
encapsulated nodule with wh
cut surface
14  21 Right 5 × 4 × 2 cm Nodular well circumscribed ru
nodule with tan yellow cut su
congestion and hemorrhageFig. 2. Desmin highlighting smooth muscle ﬁbers in a myoid hamartoma.
Three cases showed additional ﬁbrocystic changes with adenosis,
apocrine metaplasia, cyst formation, and simple ductal epithelial
hyperplasia of the usual type ranging from mild (2 cases) to mod-
erate (1 case) hyperplasia without atypia. None of our cases had any
evidence of atypical hyperplasia or malignancy whether in-situ or
invasive.
Immunohistochemical studies were performed on 4 cases;
CD34 stain was  done in one case that showed focal positivity.
S-100 protein was done on 2 cases with a negative result. P63 and
CD10 were performed on 2 cases that highlighted myoepithelial
cells. Desmin and Vimentin were done on one case and Actin was
performed on two cases of Myoid hamartomas that all resulted in
strong positivity.
Sex Diagnosis & Comment
odule F Mammary hamartoma
 nodule. Cut
an tissue with
 white ﬁbrous
F Mammary hamartoma
n nodule with F Mammary hamartoma
 F Mammary Hamartoma with focal moderate
epithelial ductal hyperplasia of the usual type
brofatty nodule F Mammary hamartoma
ith homogenous F Mammary hamartoma
lated ﬁrm nodule
face
F Myoid Hamartoma
ry tissue with
rface showing
M Mammary hamartoma
 tan tissue with
d homogenous
F Myoid hamartoma
 with irregular F Mammary hamartoma, ﬁbroadenolipoma
variant
n shiny capsule
cut surface
F Mammary hamartoma, adenolipoma variant.
With ﬁbrocystic changes including adenosis,
apocrine metaplasia, and mild usual epithelial
ductal hyperplasia without atypia
 soft nodule F Mammary hamartoma
 tan ﬁrm
ite ﬁrm whorly
F Myoid hamartoma. With Fibrocystic changes
including mild epithelial ductal hyperplasia
without atypia, adenosis, and cyst formation
bbery white tan
rface and foci of
F Mammary hamartoma. With dominance of
dense ﬁbrous tissue
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. Discussion
The word Hamartoma, Greek in origin meaning “Bodily defect”,
efers to the presence of a disorganized mixture of components
hich are endogenous to a particular site. Hamartomas are con-
idered benign non-neoplastic lesions that may  recur. They can be
ound in various locations including but not limited to the lungs,
idneys, and breasts. Breast hamartomas are composed of a random
ix  of glandular epithelial, ﬁbrous, and fatty tissue. Hogeman and
sbterg were the ﬁrst to describe the lesion back in 1968 [1], while
he actual term “hamartoma” was created in 1971 by Arrigoni et al.
n 1994, a case series done by Charpin et al. concluded that breast
amartomas account for approximately 4.8% of all benign breast
esions [2]. The exact pathogenesis for breast hamartoma develop-
ent remains a mystery. However, it is believed to be a result of a
evelopmental abnormality rather than a true neoplastic process.
n additional factor that has been noted to affect breast hamartoma
evelopment is female sex hormones; estrogen (ER) and proges-
erone (PR). Both the epithelial and stromal components of breast
amartomas may  express hormone receptors [3]. In one study, Chi-
cchio et al. reported 9 out of the 10 breast hamartoma cases to be
ositive for both estrogen and progesterone receptors, while the
emaining case showed estrogen receptor positivity and proges-
erone receptor negativity [4]. This study was later supported by
erbert et al. in 2002 who conﬁrmed the presence of both estrogen
nd progesterone receptors in all of his 24 breast hamartoma cases
5].
The lesion occurs predominantly in premenopausal women,
ostly in their 40s with a wide age range of teen age to women in
heir 80s. They are currently underdiagnosed, but with the surge of
reast lump diagnostic tools usage, the number of diagnosed cases
s on the rise.
Clinically, breast hamartomas are painless, usually mobile, soft
o ﬁrm lumps typically found in the outer breast quadrants [6]. Such
 clinical presentation often misleads physicians to think of other
ntities such as ﬁbroadenoma amongst other tumors. Nearly 60% of
reast hamartomas are non-palpable and are diagnosed radiolog-
cally. Ultrasound, mammography, magnetic resonance imaging,
ore needle and ﬁne needle aspiration biopsy are more beneﬁcial
iagnostic utilities for breast hamartomas. Ultrasound shows these
esions to be well circumscribed with a smooth border and inter-
ally being hyperechoic or of heterogenous echogenicity. Breast
amartomas lack a retrotumor acoustic phenomenon which is
ne sonographic ﬁnding used to differentiate between benign and
alignant lesions [7]. There might also be a halo separating most
esions from the surrounding tissue. This halo is mostly echogenic,
omposed of condensed breast tissue, but may  appear to be ane-
hoic, in which it is most likely formed of fat compressed between
he hamartoma and the surrounding breast tissue. In one case
eries by Georgian et al., 94% of the cases were reported to show
 thin echogenic halo [8]. On conventional T1 and T2 weighted
RI, breast hamartomas showed heterogenous intensities consis-
ent with the results of other imaging modalities in addition to a
hin capsule [9]. The appearance in mammography differs depend-
ng on the varying degree of each of its constituents. Classically, they
ppear nonhomogenous with dense nodules consisting of ﬁbrous
issue surrounded by a thin radiopaque pseudocapsule formed
rom the displaced parenchyma of the breast. Sometimes, a hamar-
oma may  appear to be homogeneously dense when it is rich in
brous tissue making it hard to distinguish from a ﬁbroadenoma,
hich is both uniformly dense and often has a thin radiolucent
apsule of compressed fat. Despite the fact that they are used to
ccurately diagnose most breast lesions, needle core biopsy and
ne needle aspiration cytology are not very helpful in diagnosing
amartomas and differentiating them from other entities which
imic  them, mainly ﬁbroadenomas. However, ﬁbroadenomas canPEN  ACCESS
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be distinguished from breast hamartomas by histological examina-
tion which typically shows the proliferation of ducts and/or stroma
resulting in an intercanalicular or pericanalicular growth. On the
other hand, breast hamartomas that consist mainly of fat may  easily
be misdiagnosed as lipoma, fat necrosis, or a cyst [10].
Grossly, the lesion is round to oval and may measure up to
20 cm in size. The cut surface mostly resembles normal breast
parenchyma or ﬁbroadenoma, again, depending on the consistency
of the lesion. Histologically, hamartomas are mostly encapsulated
whether by a true capsule or a surrounding rim of pseudocap-
sule. The lesion is lobulated and exhibits mammary ducts, lobules,
ﬁbrous tissue, and adipose tissue in varying proportions. Some
cases may  show additional changes including pseudoangiomatous
stromal hyperplasia (PASH), and prominent smooth muscle prolif-
eration [3].
A rare subtype of breast hamartomas is myoid hamartoma,
which is known to contain varying amounts of smooth muscle cells
within its stroma. They are typically well-circumscribed lesions
that clinically appear to be ﬁrm, mobile, well demarcated, and of
high density in mammography. Myoid hamartomas are considered
to be an exclusively female tumor; however, one single case in a
male patient has been reported by Ravakhah et al. [11]. The ori-
gin of the smooth muscle seen in these hamartomas has not been
fully supported in detail by any study in literature; yet poten-
tial sources include blood vessel walls, areolar muscularis tissue,
undifferentiated breast stroma, and myoepithelial cells. Another
hypothesis concerning the origin of smooth muscle is by meta-
plasia of the breast stromal cells. Presence of CD34 is believed
to be a crucial indicator of metaplasia of breast stromal cells
into smooth muscle [12]. Other immunohistochemical markers
commonly sought out in breast hamartomas, speciﬁcally myoid
hamartomas, include desmin, vimentin, and SMA. The general
belief however is that myoid hamartomas reﬂect nodular scleros-
ing adenosis with hyperplasia of myoid myoepithelial cells by some
and an adenomyoepithelioma by others [13].
There were attempts in the past to try to classify breast
hamartomas into speciﬁc categories based on their histological
appearance. Fibrous, fatty, and ﬁbro-fatty were the categories cre-
ated by McGuire et al., while adenolipoma, ﬁbroadenoma-like,
ﬁbroadenoma with a ﬁbrous stroma, and encapsulated ﬁbrocystic
changes were categories created by Jones et al. [2]. These classiﬁca-
tions are not generally accepted by most authorities, mostly since
they are not really easily reproducible and have no clinical impact.
Very seldom, breast hamartomas have been associated with
malignancies. Only a few cases are reported in literature of breast
hamartomas that are associated with in-situ or even invasive car-
cinomas.
Hamartomas are mostly benign lesions with recurrence seen in
8% of cases. It is speculated that these cases most likely represent
multifocal disease rather than true recurrence.
Multiple breast hamartomas have been associated with certain
genetic abnormalities, speciﬁcally Cowden syndrome which is also
known as Multiple Hamartoma syndrome. Genetic data is limited;
however, alterations involving chromosomal regions 12q12-15 and
6p21 have been described in literature [3].
Today, surgical excision of breast hamartomas is considered
to be curative. Generally, they have an excellent prognosis with
or without surgical excision. Some suggest merely observing the
hamartoma without excision if diagnosis can be conﬁrmed by
mammography [14]; however, since there have been reports of
malignancies associated with breast hamartomas, the general rec-
ommendation is surgical excision of the lesion. Seeing as most of
these breast hamartomas are circumscribed, often encapsulated
with well-delineated borders, they can be easily enucleated [13].
Post-operatively, patients are suggested to follow up with mam-
mography and ultrasound every 6 months for 1–2 years to ensure
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tability of their current condition and monitor for any recurrence
15].
. Conclusion
Breast hamartoma is a rare benign lesion composed of varying
egrees of normal breast components including glandular, fatty,
nd ﬁbrous tissue. It is underdiagnosed and thus underreported.
owever, there are increasing rates of breast hamartoma diagnoses
ue to the huge surge of usage of breast diagnostic procedures such
s ultrasound and mammography. Breast hamartomas are rarely
ssociated with malignancies, and excision is considered curative.
et recurrence is seen in about 8% of reported cases. Clinicians in
articular surgeons need to be aware of this entity as a differential
iagnosis of a breast mass in particular if it is well demarcated.
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